Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Frequently asked questions
What sector does Kancera AB (publ) (KAN) operate in?
Kancera AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kancera AB (publ) (KAN) current stock price?
As of the latest data, Kancera AB (publ) stock price is SEK 0.16, with a previous close of SEK 0.16.
What is Kancera AB (publ) (KAN) current market capitalization?
Kancera AB (publ) market cap is approximately 19.37 million.
What is Kancera AB (publ) (KAN) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.33.
Does Kancera AB (publ) (KAN) pay dividends?
No. Kancera AB (publ) does not pay a dividend.
What is Kancera AB (publ) (KAN) beta (volatility) score?
Kancera AB (publ) has a beta of 0.915, meaning its volatility is roughly in line with the market.
